Our research is focused on: 1. Identifying genetic markers for chemotherapy induced adverse drug reactions 2. the toxicity of new psychoactive substances & how to use post-mortem metabolomics. We develop prediction models using massive parallel sequencing, single cell RNASeq & high resolution chromatin conformation capture and bioinformatics with large clinical cohorts. In forensics, we develop new techniques using the CBRS platform for neuropharmacology as well as post-mortem metabolomics.
Henrik Green
Linköping University
Key Publications
5‐HT2A receptor agonism by tert‐leucinamide and valinamide synthetic cannabinoids: In vitro and in vivo evidence
British Journal of Pharmacology, 2026
Development and analytical validation of a targeted short‐read next generation sequencing‐based pharmacogenetic panel for comprehensive variant detection
British Journal of Pharmacology, 2026
Comprehensive in vitro profiling of traditional and emerging stimulants at monoamine transporters and the 5‐HT2A receptor
British Journal of Pharmacology, 2026
Fatal intoxications with nitazenes: postmortem findings, toxicology, and in vitro characterization at the μ-opioid receptor of six nitazene analogues
Archives of Toxicology, 2026
In Vitro Metabolism of Δ8‐, Δ9‐, and Δ10‐THC in Human Hepatocytes: Distinct Δ10‐THC Biotransformation and Implications for Drug Testing
Drug Testing and Analysis, 2026